MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Closed

SectorHealthcare

3.59 6.21

Overview

Share price change

24h

Current

Min

3.31

Max

3.63

Key metrics

By Trading Economics

Income

-15M

-40M

Sales

8.2M

50M

Profit margin

-80.43

Employees

435

EBITDA

-19M

-42M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+17.99% upside

Dividends

By Dow Jones

Next Earnings

11 maj 2026

Market Stats

By TradingEconomics

Market Cap

4.2M

1.1B

Previous open

-2.62

Previous close

3.59

News Sentiment

By Acuity

50%

50%

135 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 kwi 2026, 23:49 UTC

Major News Events

New Zealand 1Q Inflation Higher Than Expected

20 kwi 2026, 23:10 UTC

Hot Stocks

Stocks to Watch: Amazon, Alaska Air Group, BridgeBio Oncology, AXT

20 kwi 2026, 22:53 UTC

Major Market Movers

BridgeBio Oncology Shares Rise After FDA Fast-Tracks Pancreatic Cancer Treatment

20 kwi 2026, 23:45 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

20 kwi 2026, 23:44 UTC

Market Talk

Gold Consolidates as End of Cease-Fire Looms -- Market Talk

20 kwi 2026, 23:39 UTC

Market Talk

Rio Tinto Posts Strong Start to Year -- Market Talk

20 kwi 2026, 23:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 kwi 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

20 kwi 2026, 23:30 UTC

Market Talk

Super Retail's Earnings Outlook Less Rosy -- Market Talk

20 kwi 2026, 23:09 UTC

Market Talk

Viva Energy's Refinery Fire More Benign Than Jefferies Thought -- Market Talk

20 kwi 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20 kwi 2026, 22:26 UTC

Acquisitions, Mergers, Takeovers

West African Resources Says Sanbrado, Toega Operations Not Subject to Govt Request for Additional Participation

20 kwi 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

West African Resources Plans to Distribute Cash Proceeds to Shareholders Via Special Dividend

20 kwi 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

West African Resources Aims for Acquisition to Be Completed by End-2026

20 kwi 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

West African Resources Says to Work Cooperatively With Govt to Finalize Deal Terms

20 kwi 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

West African Resources Says Acquisition Would Be for A$175 Million

20 kwi 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

West African Resources Says Burkina Faso Govt Issues Decree to Acquire 25% of Kiaka

20 kwi 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20 kwi 2026, 22:01 UTC

Acquisitions, Mergers, Takeovers

Amazon Invests $5B in Anthropic Amid Expanded Collaboration

20 kwi 2026, 21:38 UTC

Market Talk

Apple's New CEO Will Face Immediate Pressure on AI Strategy -- Market Talk

20 kwi 2026, 21:33 UTC

Acquisitions, Mergers, Takeovers

Uber Expands Stake In Lucid for Robo-Taxis. This Is How Tesla's Stock Is Responding. -- Barrons.com

20 kwi 2026, 21:24 UTC

Market Talk

Apple's CEO Change Timing Will Garner Mixed Reaction, Analyst Says -- Market Talk

20 kwi 2026, 21:24 UTC

Market Talk

Global Equities Roundup: Market Talk

20 kwi 2026, 21:13 UTC

Earnings

Alaska Air: Expansion of Card Portfolio Expected to Accelerate Loyalty Platform Beyond Incremental $150M Profit Outlined in Alaska Accelerate Strategy

20 kwi 2026, 21:10 UTC

Earnings

Alaska Air to Move Toward a Single Issuer for Atmos Rewards Credit Cards

20 kwi 2026, 21:09 UTC

Earnings

Alaska Air Sees 2Q Capacity Up About 1% Year-Over-Year, Down Nearly a Point From Original Views, on 'Proactive Trimming' of May and June Capacity

20 kwi 2026, 21:08 UTC

Earnings

Alaska Air 'Continues to Operate From a Position of Strength,' With Healthy Balance Sheet, Strong Liquidity, About $20B in Unencumbered Assets

20 kwi 2026, 21:07 UTC

Earnings

Alaska Air: Taken Together, Rev, Cost and Fuel Assumptions Result in 2Q Adjusted Loss Per Share Estimate of About $1

20 kwi 2026, 21:05 UTC

Earnings

Alaska Air: This Assumption Adds About $600M of Expense to 2Q, Equivalent to EPS Headwind of $3.60

20 kwi 2026, 21:05 UTC

Earnings

Alaska Air Expects 2Q Fuel Cost to Average About $4.50 Based on Forward Curve Today

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

17.99% upside

12 Months Forecast

Average 4 USD  17.99%

High 5 USD

Low 3 USD

Based on 6 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

2.02 / 2.115Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

135 / 348 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat